3 -11 (85) 2025 - Lipartiya M.G. - ANEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE ON THE BACKGROUND OF ERYTHROPOIETIN THERAPY

ANEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE ON THE BACKGROUND OF ERYTHROPOIETIN THERAPY

Lipartiya M.G. - Tashkent State Medical University

Resume

The paper examines the pathogenetic mechanisms of anemia in chronic kidney disease, including endogenous erythropoietin deficiency, impaired iron metabolism, and the effects of uremic intoxication and inflammatory factors. Special attention is given to the role of hepcidin and cytokines in the development of functional iron deficiency. The mechanisms of action, classification, and clinical significance of erythropoietin therapy are described, emphasizing its effectiveness and the need for an individualized approach to the treatment of patients with chronic kidney disease.

Key words: anemia; chronic kidney disease; erythropoietin; hepcidin; iron deficiency; cytokines; hematopoiesis; erythropoietin therapy.

First page

12

Last page

16

For citation:Lipartiya M.G. - ANEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE ON THE BACKGROUND OF ERYTHROPOIETIN THERAPY//New Day in Medicine 11(85)2025 12-16 https://newdayworldmedicine.com/en/new_day_medicine/11-85-2025

List of References

  1. Бобкова И.Н., Мухин Н.А. Анемия при хронической болезни почек: современные подходы к диагностике и лечению // Нефрология и диализ. 2021;23(4]:293-302.
  2. Козловская Н.Л., Сидорова Ю.А. Эритропоэтиновая терапия при хронической почечной недостаточности: эффективность и безопасность // Клиническая медицина. 2020;98(5)25-30.
  3. Locatelli F., Bárány P., Covic A. et al. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease // Kidney International Supplements. 2021;11(1):1-136.
  4. Macdougall I.C., Eckardt K.-U. Anaemia in chronic kidney disease: new treatment strategies // Nature Reviews Nephrology. 2022;18:133-147.
  5. Кузнецова Н.М., Мартынова Е.В. Патогенез анемии при хронической болезни почек: роль дефицита железа и воспаления // Терапевтический архив. 2019;91(7):54-59.
  6. Stauffer M.E., Fan T. Prevalence of anemia in chronic kidney disease in the United States // PLoS ONE. 2024;9(1):e84943.
  7. Михайлова Н.В. Эритропоэтины в лечении анемий почечного генеза: современные возможности и ограничения // Вестник клинической фармакологии. 2022;3:41-46.
  8. Babitt J.L., Lin H.Y. Mechanisms of anemia in CKD // Journal of the American Society of Nephrology. 2022;23(10):1631-1634.
  9. Тареева И.Е. Нефрология: руководство для врачей. - М.: ГЭОТАР-Медиа, 2020; 864 стр.
  10. Weiss G., Goodnough L.T. Anemia of chronic disease // New England Journal of Medicine. 2024;352:1011-1023.

    file

    download